Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

SEC Filing Summary: Ekso Bionics Holdings, Inc.

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on January 22, 2018. The filing discloses a leadership transition within the Company, specifically the departure of the President of the EksoWorks business unit. The report was signed by Maximilian Scheder-Bieschin, Chief Financial Officer, on January 26, 2018.

Key Financial Metrics

The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation and severance package for the departing executive:

  • Final Wages and Accrued Payments: $36,063 (less withholdings).
  • Severance Payment: $232,000 to be paid over a 12-month period.
  • 401(k) Matching Contribution: Estimated at 7,826 shares for the year ended December 31, 2017.
  • Stock Options: Accelerated vesting for options that would have vested during the 12-month separation period.

Material Changes

The primary material change reported is the resignation of Russdon Angold as President of the EksoWorks business unit and from all other positions with the Company, effective January 22, 2018. This departure is part of a broader leadership transition announced by the Company.

Outlook, Risks, and Unusual Items

Management Commentary and Transition: The Company entered into a Separation Agreement to facilitate a smooth transition. Mr. Angold has agreed to assist the Company and its advisors during the 12-month separation period. A press release detailing the leadership transition was issued on January 26, 2018.

Restrictions and Contingencies:

  • Stock Lock-up: Mr. Angold agreed not to sell or dispose of his Common Stock for 90 days following his resignation, with exceptions for gifts and pre-approved dispositions.
  • Confidentiality: Mr. Angold remains subject to restrictions regarding interference with business, use of confidential information, and assignment of inventions.
  • Release of Claims: The agreement includes a mutual release of claims related to employment and separation.

Investor Verification Checklist

  • Verify the full text of the Separation Agreement (Exhibit 99.1) for specific terms regarding the 401(k) share count and stock option acceleration.
  • Review the press release dated January 26, 2018 (Exhibit 99.2) for details on the new leadership structure and strategic direction.
  • Confirm the impact of the leadership change on the EksoWorks business unit's operational performance in subsequent quarterly reports.
  • Note that the filing does not contain updated financial statements or guidance; refer to the most recent 10-K or 10-Q for financial health.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.